Drug intelligence / Profile preview

chlorclobutinamide

Development stage: Unknown
Lead developer: Beijing Bolivikon Pharmaceutical Research Institute
Modality: Small Molecules
Administration: Oral

Overview

Chlorclobutinamide is a small molecule antiepileptic drug candidate developed by the Beijing Bolivikon Pharmaceutical Research Institute. It is a butyramide derivative currently being evaluated for the treatment of epilepsy. Clinical development has primarily taken place in China, including Phase 1 pharmacokinetic and safety studies (such as trial CTR20140139). The drug is designed to modulate neuronal excitability, potentially through the enhancement of GABAergic inhibitory neurotransmission or the stabilization of ion channels, although its precise molecular target remains to be fully characterized in public clinical literature.

Other names: 氯氯丁酰胺

Beyond the preview

Go deeper on chlorclobutinamide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on chlorclobutinamide.

Explore the full profile